Filing identity and reporting period
The supplied filing identifies the registrant as Isoray, Inc., not Perspective Therapeutics, Inc. It is a Form 10-Q for the quarter ended March 31, 2021, covering Isoray’s fiscal third quarter and nine months ended March 31, 2021. This conflicts with the request metadata identifying Perspective Therapeutics and “2020 Q3.”
Business context and financial results
Isoray manufactures and sells Cesium-131 brachytherapy seeds and related products, including for prostate and other cancers. Unless otherwise stated, amounts below are in millions of dollars.
| Metric | Three months ended Mar. 31, 2021 | Prior-year quarter | Nine months ended Mar. 31, 2021 | Prior-year period |
|---|---|---|---|---|
| Net sales | $2.600 | $2.880 | $7.343 | $7.401 |
| Gross profit / margin | $1.362 / 52% | $1.706 / 59% | $3.775 / 51% | $4.053 / 55% |
| Operating loss | $(0.766) | $(0.548) | $(2.353) | $(2.287) |
| Net loss | $(0.745) | $(0.545) | $(2.326) | $(2.258) |
| Loss per share, basic and diluted | $(0.01) | $(0.01) | $(0.03) | $(0.03) |
Cash used in operating activities was $1.719 million for the nine-month period, versus $2.793 million a year earlier; investing activities used $0.272 million. Financing provided $64.441 million, primarily from equity offerings and warrant exercises. Cash and cash equivalents were $64.841 million at March 31, 2021, compared with $2.392 million at June 30, 2020; including restricted cash, period-end cash was $65.023 million. Working capital was $66.158 million and the current ratio was 35.53.
Total liabilities were $3.182 million, including lease liabilities of $0.838 million; the filing reports no conventional borrowings. Total assets were $71.280 million. The accumulated deficit was $90.264 million.
Material changes versus prior comparable periods
- Quarterly sales declined 10%; nine-month sales declined 1%. Prostate brachytherapy sales fell 16% in the quarter and 10% over nine months, while other sales rose 20% and 59%, respectively.
- Gross margin fell to 52% from 59% in the quarter and to 51% from 55% over nine months. Management attributed pressure to lower sales, higher isotope and freight costs, and production labor costs.
- Quarterly operating loss widened to $0.766 million from $0.548 million; the nine-month operating loss increased modestly to $2.353 million from $2.287 million.
- Cash rose sharply following equity financing. Common shares outstanding increased from 68.9 million at June 30, 2020 to 141.5 million at March 31, 2021, reflecting offerings and exercises of warrants and options.
Outlook, commentary, risks, and unusual items
- Management said it missed its target of approximately 25% fiscal 2021 revenue growth during the first nine months. It conditionally anticipates cash-flow break-even in three to four years if targeted growth is achieved and sustained; it cautioned there is no assurance this will occur.
- After the February 2021 offering, management did not anticipate needing additional capital to finance operations for the next fiscal year. Future financing, if required, could dilute shareholders.
- COVID-19-related restrictions and hospitals’ focus on the pandemic delayed or canceled procedures, particularly prostate treatments. Management reported customer indications of possible procedure recovery but gave no assurance of a sustained rebound.
- Cesium-131 supply depends on Russian sources and international transport. One of the two historical Russian reactors remained shut down during 2021 for an indeterminate period, creating supply and logistics risks. A new supplier contract runs through March 31, 2023.
- Other-treatment growth is subject to variability, physician adoption, and reimbursement. The filing describes uncertainty about the impact of Medicare’s Radiation Oncology Alternative Payment Model and whether reimbursement will support certain procedures.
- Three customers accounted for approximately 41% of nine-month revenue; one physician-group customer cluster represented approximately 26%. The filing also reports that no legal proceedings were disclosed, no off-balance-sheet arrangements existed, and management concluded disclosure controls were effective.
Important facts for investors to verify
- Confirm the issuer and period: the supplied filing is Isoray’s March 31, 2021 Form 10-Q, not a Perspective Therapeutics 2020 Q3 filing.
- Review the timing and reliability of Cesium-131 supply, including the Russian reactor shutdowns and terms of the new supply contract.
- Assess whether procedure volumes and prostate revenue recover from pandemic-related disruption, and whether growth in other applications can continue.
- Verify customer concentration and reimbursement developments, including the effect of Medicare payment rules on adoption and pricing.
- Evaluate cash burn against management’s conditional break-even outlook and account for the substantial share-count increase from financing.